To investigate whether virus contained genetic markers associated with resistance to antiviral drugs, a conventional genotyping assay (sequencing) was performed, and neuraminidase (NA) and matrix 2 genes were sequenced. All 11 patients had virus with a histidine-to-tyrosine mutation at residue 275 of the NA protein (H275Y); 1 patient also had virus with an I117M mutation ( Figure) . Detailed molecular epidemiologic data and genetic characteristics of the isolates are described elsewhere (2) .
Of the 11 patients, 6 were <59 months of age and 5 had underlying immunosuppressive conditions; only 1 patient was immunocompetent and >59 months of age (Table) . Three patients from whom samples before and after treatment with oseltamivir were available showed evidence of having acquired the H275Y mutation during oseltamivir therapy. None of the 11 patients received oseltamivir chemoprophylaxis.
We also tested 100 persons who had contact with the 11 patients for possible transmission of drug resistance. Eight of 100 were confirmed as having been infected with pandemic (H1N1) 2009 virus before the 11 patients were infected. Influenza-like illnesses developed in the 11 patients a median of 2 days (range 1-7 days) after the 8 contact persons were confirmed as having pandemic (H1N1) 2009. Five of the 8 contact patients were children; none had an immunosuppressive condition or were given oseltamivir chemoprophylaxis before illness; and 7 of 8 were <59 months of age. Oseltamivir-resistance tests were not performed for these 8 patients because they all received oseltamivir therapy and their clinical symptoms resolved.
Therefore, the possibility of transmitted resistance from contact patients was not demonstrated in this study.
All 11 patients were initially given the usual dose of oseltamivir (75 mg 2×/day in adults). After detection of oseltamivir resistance, treatment regimens were as follows: 3 patients were given high-dose oseltamivir (150 mg 2×/day in adults), 3 patients were given combination therapy (oseltamivir and amantadine; oseltamivir and peramivir; and oseltamivir, amantadine, and ribavirin, respectively); 3 patients were given zanamivir nasally; and 2 patients continued to receive oseltamivir.
Seven of the 11 patients had complications during treatment: 6 had viral or secondary bacterial pneumonia and 1 had acute respiratory distress syndrome (Table) . Three patients died of pandemic (H1N1) 
Conclusions
Our nationwide surveillance of drug-resistant pandemic (H1N1) 2009 in South Korea indicated that most patients were children (<59 months of age) or immunocompromised. All isolates had the H275Y mutation in the NA protein, and 1 isolate also had the I117M mutation in the same protein.
Our finding that oseltamivir resistance developed in immunocompromised patients is consistent with those of recent case reports that described development of oseltamivir resistance in immunosuppressed patients receiving this drug (3, 4) . A recent study in Australia reported that 4 of 32 adult oncology and hematology patients were infected with oseltamivir-resistant virus with the H275Y mutation (5). In 3 of our patients (patients 3, 5, and 11) drug-resistant isolates appeared <5 days after initiation of oseltamivir therapy. Thus, we suggest that physicians be alert to emergence of oseltamivir-resistant pandemic (H1N1) 2009, particularly if there is treatment failure with oseltamivir or prolonged viral shedding is evident.
More than half of our patients were <59 months of age, indicating that a younger age may be a risk factor for infection with drug-resistant pandemic (H1N1) 2009. Clinical trials have reported oseltamivir resistance in <5.5% of children with seasonal influenza (6) . Explanations for the higher rate of drug resistance in children than in adults are that children have a more protracted course of influenza, longer viral shedding times, and higher viral titers (7) . Another explanation might be that we cannot rule out suboptimal dosing of oseltmaivir in children, although World Health Organization dose standards were used (8) and all pharmacies were given instructions on emergency compounding of oseltmaivir.
Development of resistance appeared to be caused by sporadic mutations. We found no evidence of transmission. Availability of pretreatment and posttreatment samples indicated that resistance to oseltamivir developed during treatment in >3 patients. One case report (9), 1 report of a cluster of cases in Vietnam (10), and 1 outbreak in a hematologic ward (11) documented patient-to-patient transmission of oseltamivir-resistant virus. One of our patients was infected with virus that had a novel NA mutation (I117M). A previous study indicated that the I117V mutation in avian influenza virus (H5N1) was associated with low-level oseltamivir resistance (12) . The I117M mutation of NA may contribute to oseltamivir resistance, but it is not clear whether isolates with these 2 NA mutations have higher levels of resistance or virulence than the H275Y NA mutant.
We found few patients with drug-resistant pandemic (H1N1) 2009 in South Korea. However, our study was based on the nationwide surveillance system for drug resistance among influenza-related symptoms (nasal stiffness, sore throat, cough, myalgia, fatigue, headache, and fever) that were absent or mild. All doses of oseltamivir were given 2×/d. ED, emergency department.
